Moreover, studies by Burkhart and colleagues revealed that reversan, an inhibitor of MRP1 when used in combination with vincristine and etoposide increased tumor sensitivity to these conventional drugs in murine models of neuroblastoma (syngeneic and human xenografts) with no increase in toxicity levels of these conventional agents (Burkhart et al., 2009). The gene discussed is ABCC1; the disease is neuroblastoma.